Oracle or false prophet? Can we predict AAV efficacy based on preexisting antibody titers?
Res Pract Thromb Haemost
.
2019 Feb 28;3(2):149-151.
doi: 10.1002/rth2.12190.
eCollection 2019 Apr.
Authors
Xavier M Anguela
1
,
Katherine A High
1
Affiliation
1
Research & Development Spark Therapeutics Philadelphia Pennsylvania.
PMID:
31011696
PMCID:
PMC6462742
DOI:
10.1002/rth2.12190
No abstract available